Dialog Solutions Joins California Life Sciences Association (CLSA)

Dialog Solutions, a division of ProQuest, has joined the California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector.

CLSA, California’s largest and most influential life sciences advocacy and business leadership organization, works with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, along with research universities and institutes, investors and service providers throughout the state.

Dialog is a powerful content platform with an intuitive interface for both end-users and information professionals – including command-line queries for powerful precision search. They’ll also have access to Drug Safety Triager, a validated SaaS-based solution that seamlessly ingests Dialog alert results with an audit trail to support efficient, consistent and timely review of literature.

“We’re proud to join CLSA, an organization that supports our mission to provide easy access to authoritative literature, workflow tools and tailored services with flexible access models,” said Michael Rai, General Manager of Dialog Solutions. “Life sciences companies around the world benefit from specially Dialog’s peer-reviewed scientific literature, tools to simplify literature workflows, and specialized literature services from on-hand experts.”

“We welcome Dialog Solutions to the California Life Sciences Association (CLSA) family of members. The work Dialog is engaged in is an important component of life sciences innovation, particularly the content, workflow tools and outsourcing services they bring to the table to improve patient safety,” said Mike Guerra, President & CEO, California Life Sciences Association (CLSA). “Our entire membership is focused on ensuring that California continues to be the gold standard for life sciences for the world – advancing science and creating new therapies and technologies that benefit patients.”